Temozolomide (NSC 362856), DNA Alkylator

Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.

Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma

Where to Buy 85622-93-1

Temozolomide CAS 85622-93-1 Manufacturers, Suppliers, Factory - Home Sunshine Pharma

Human Methyl Purine DNA Glycosylase and DNA Polymerase β Expression Collectively Predict Sensitivity to Temozolomide

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Temozolomide (NSC 362856), DNA Alkylator

Current and future developments in the use of temozolomide for the treatment of brain tumours - The Lancet Oncology

PDF) Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma - Quinn - 2009 - Cancer - Wiley Online Library

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations